Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPAR and Identification of TUSC5 Coding Variants in Lean and Obese Humans
Figure 3
Subcutaneous WAT mRNA Expression for Tusc5 is not Increased in Type 2 Diabetic Subjects Treated 11 Weeks with Pioglitazone (PIO). Samples of subcutaneous WAT were biopsied before and after treatment with placebo (: 7 male, 9 female) or PIO (: 5 male, 11 female) and relative abundance of Tusc5 transcript was determined, using placebo group baseline expression as comparator. No change was observed in Tusc5 expression, in contrast to increases observed in mRNA levels for phosphoenolpyruvate carboxykinase 1 (PEPCK1/Pck1) and lipoprotein lipase (LPL) (†). Values are means SEM.
